GlaxoSmithKline is to pay $57 million (£35 million) for Genelabs, California-based specialists in infectious diseases, including hepatitis C. The companies …
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

